831 Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies

831 Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies

Bibliographic Details
Main Authors:	Yin Wang, Wei Shi, Di Zhao
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
by: Carla Colombo, et al.
Published: (2022-09-01)

LSD1 is a targetable vulnerability in gastric cancer harboring TP53 frameshift mutations
by: Suzeng Wang, et al.
Published: (2025-02-01)

Mesonephric Adenocarcinoma of the Vagina Harboring <i>TP53</i> Mutation
by: Hyunjee Lee, et al.
Published: (2022-01-01)

KDM4C-mediated senescence defense is a targetable vulnerability in gastric cancer harboring TP53 mutations
by: Kaiqing Wang, et al.
Published: (2023-10-01)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
by: Daniel J. Turnham, et al.
Published: (2020-10-01)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
by: Hao Sun, et al.
Published: (2020-10-01)

Follicular thyroid cancer harboring TERT and TP53 mutations: A case report
by: Jing Zhang, et al.
Published: (2023-08-01)

Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review
by: Stefaniuk P, et al.
Published: (2021-02-01)

Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.
by: Wassim Abou-Kheir, et al.
Published: (2011-01-01)

The impact of TP53 and PTEN tumor suppressor genes on response to different breast cancer treatment modalities
by: Nikola Tanić, et al.
Published: (2022-12-01)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
by: Melania Tesio
Published: (2023-02-01)

Therapeutic targeting of TP53 nonsense mutations in cancer
by: Charlotte Strandgren, et al.
Published: (2024-05-01)

Investigating molecular vulnerabilities in TP53-mutant transformed myeloproliferative neoplasms
by: Paterson, A
Published: (2024)

RNA and phosphoprotein profiles of TP53- and PTEN-knockouts in MCF10A at baseline and responding to DNA damage
by: ChenWei Lin, et al.
Published: (2024-01-01)

TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro
by: Sanjay K. Singh, et al.
Published: (2023-10-01)

Immunohistochemical Analysis of TP53 and PTEN Expression in Glioblastoma Multiforme Patients of Western Rajasthan, India: An Observational Study
by: Garima, et al.
Published: (2022-08-01)

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
by: Marta Garcia de Herreros, et al.
Published: (2024-12-01)

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
by: Zin W. Myint, et al.
Published: (2021-09-01)

Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
by: Taisuke Imamura, et al.
Published: (2022-04-01)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
by: Haiwei Wang, et al.
Published: (2022-06-01)

Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines
by: Anne Huber, et al.
Published: (2024-08-01)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
by: Stephen L. Abrams, et al.
Published: (2022-02-01)

Mutational Landscape and In-Silico Analysis of TP53, PIK3CA, and PTEN in Patients with Breast Cancer from Khyber Pakhtunkhwa
by: Hilal Ahmad, et al.
Published: (2023-11-01)

Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia
by: Yu-Hung Wang, et al.
Published: (2024-07-01)

TP53BP2: Roles in suppressing tumorigenesis and therapeutic opportunities
by: Yunfei Huo, et al.
Published: (2023-09-01)

The TP53 fertility network
by: Diego d'Avila Paskulin, et al.
Published: (2012-01-01)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
by: Dmitriy Sonkin
Published: (2015-10-01)

Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity
by: Alberto Toso, et al.
Published: (2014-10-01)

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN
by: Angelos Heldin, et al.
Published: (2023-12-01)

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
by: Qiong Lyu MD, et al.
Published: (2020-12-01)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
by: Jie Zhou, et al.
Published: (2022-08-01)

6.831 User Interface Design and Implementation, Fall 2004
by: Miller, Robert
Published: (2004)

dic(7;9) with loss of Tp53 gene in acute lymphoblastic leukemia
by: Anurag Gupta, et al.
Published: (2016-01-01)

Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants
by: Aslı Subaşıoğlu, et al.
Published: (2023-01-01)

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
by: Qi Shen, et al.
Published: (2024-12-01)

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies
by: Marianna B. Ruzinova, et al.
Published: (2019-08-01)

The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers
by: Magali Olivier, et al.
Published: (2007-02-01)

Germline mutations of TP53 gene can be a key factor in prostate cancer genesis
by: Kawtar Aboulalaa, et al.
Published: (2024-10-01)

Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling
by: Catarina Macedo-Silva, et al.
Published: (2023-10-01)

Long Noncoding RNA GATA3-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Suppression of PTEN, CDKN1A, and TP53
by: Xuee Luo, et al.
Published: (2019-01-01)